Cell and Gene Therapy Third-Party Logistics Market

Cell and Gene Therapy Third-Party Logistics Market Forecast and Outlook 2025 to 2035

The global cell and gene therapy third-party logistics market is projected to rise from USD 11.9 billion in 2025 to about USD 34.9 billion by 2035, recording an absolute increase of USD 23.0 billion during the assessment period. This represents total growth of 193.3% and a compound annual growth rate of 11.4%.

The market size is expected to reach nearly 2.9 times its 2025 level, supported by increasing demand for specialised cold chain logistics, broader adoption of advanced cell and gene therapies, and sustained emphasis on temperature-controlled distribution across global healthcare systems. Expansion of clinical trials, commercial therapy launches, and patient-specific treatment requirements continues to shape demand for logistics solutions that maintain consistent temperature integrity and traceability.

Quick Stats for Cell and Gene Therapy Third-Party Logistics Market

• Cell and Gene Therapy Third-Party Logistics Market Value (2025): USD 11.9 billion
• Cell and Gene Therapy Third-Party Logistics Market Forecast Value (2035): USD 34.9 billion
• Cell and Gene Therapy Third-Party Logistics Market Forecast CAGR: 11.4%
• Leading Type in Cell and Gene Therapy Third-Party Logistics Market: Clinical (83.3%)
• Key Growth Regions in Cell and Gene Therapy Third-Party Logistics Market: Asia Pacific, Europe, and North America
• Key Players in Cell and Gene Therapy Third-Party Logistics Market: Cencora Corporation, Cardinal Health, McKesson Corporation, EVERSANA, Knipper Health, DHL, Kuehne + Nagel, Arvato SE, FedEx, United Parcel Service (UPS)

Clinical logistics account for 83.3% of market share, reflecting their central role in supporting clinical trial distribution and treatment programme coordination. Cell therapies represent 65.5% of this category, influenced by extensive clinical validation and growing procedural volumes in regenerative medicine and personalised oncology.

Adoption of ambient storage solutions remains notable at 35.3%, particularly in applications involving documentation, ancillary materials, and temperature-stable components where compatibility with existing storage infrastructure and lower handling costs is preferred. Advances in cold chain monitoring, temperature-regulation equipment, and real-time tracking platforms contribute to improved product integrity and delivery reliability across regional and international supply routes.

Therapeutic area patterns show oncology holding 51.3% of demand, driven by the requirements of CAR-T therapies and personalised treatment models needing precise environmental controls during collection, processing, and distribution. Neurology holds 20.2% share and reflects the complex handling needs of fragile biological materials often requiring narrow temperature ranges.

Cardiovascular diseases account for 10.9% and ophthalmology for 7.6%, with each segment influenced by unique transport conditions and workflow arrangements. End-use segmentation shows biopharmaceutical companies accounting for 60.5% of market share due to their manufacturing scale, regulatory obligations, and reliance on integrated distribution networks capable of supporting specialised therapies.

Asia Pacific leads market expansion influenced by biopharmaceutical growth, localised clinical trials, and continued investment in healthcare infrastructure. India is projected to grow at 13.5% CAGR and China at 12.8%, supported by development of advanced therapy manufacturing capabilities and national programmes promoting biotechnology expansion. Brazil records 10.5% CAGR, shaped by increased healthcare investment and integration of cell and gene therapy logistics into regional pharmaceutical operations.

Mature healthcare systems, including the USA at 10.8% CAGR, Germany at 9.7%, the UK at 10.2%, and Japan at 11.9%, maintain steady demand due to commercial therapy availability, ongoing regulatory oversight, and the need for specialised distribution protocols aligned with established quality standards. These conditions collectively contribute to continued development of third-party logistics services supporting cell and gene therapy deployment across global healthcare networks.

Between 2025 and 2030, the cell and gene therapy third-party logistics market is projected to expand from USD 11.9 billion to USD 20.4 billion, resulting in a value increase of USD 8.5 billion, which represents 37.0% of the total forecast growth for the decade. This phase of development will be shaped by rising demand for clinical trial support expansion, increasing applications in commercial therapy distribution, and growing penetration in specialized cold chain solutions. Logistics providers are expanding their capabilities to address the growing demand for temperature-controlled and time-sensitive distribution systems in various therapeutic applications and operational categories.

From 2030 to 2035, the market is forecast to grow from USD 20.4 billion to USD 34.9 billion, adding another USD 14.5 billion, which constitutes 63.0% of the overall ten-year expansion. This period is expected to be characterized by the expansion of automated cold chain systems, the integration of innovative tracking technologies, and the development of specialized solutions for specific therapeutic segments. The growing adoption of personalized medicine standards and global distribution mandates will drive demand for ultra-reliable logistics systems with enhanced temperature control specifications and consistent operational characteristics.

Cell and Gene Therapy Third-Party Logistics Market Key Takeaways

Metric	Value
Estimated Value in (2025E)	USD 11.9 billion
Forecast Value in (2035F)	USD 34.9 billion
Forecast CAGR (2025 to 2035)	11.4%

Why is the Cell and Gene Therapy Third-Party Logistics Market Growing?

Market expansion is being supported by the increasing demand for specialized cold chain logistics solutions and the corresponding need for high-quality third-party logistics services in cell and gene therapy applications across global healthcare operations.

Modern biopharmaceutical companies are increasingly focused on advanced logistics systems that can ensure product integrity, maintain strict temperature controls, and enhance distribution reliability while meeting stringent regulatory requirements.

The proven efficacy of specialized third-party logistics in various therapeutic applications makes them an essential component of comprehensive commercialization strategies and patient access programs.

The growing emphasis on temperature control and supply chain optimization is driving demand for ultra-reliable logistics services that meet stringent performance specifications and operational requirements for cell and gene therapy applications.

Biopharmaceutical companies' preference for dependable, high-performance distribution systems that can ensure consistent product quality is creating opportunities for innovative logistics solutions and customized cold chain services.

The rising influence of regulatory guidelines and quality protocols is also contributing to increased adoption of premium-grade third-party logistics services across different therapeutic applications and distribution networks requiring advanced temperature management technology.

Opportunity Pathways - Cell and Gene Therapy Third-Party Logistics Market

The cell and gene therapy third-party logistics market represents a specialized growth opportunity, expanding from USD 11.9 billion in 2025 to USD 34.9 billion by 2035 at an 11.4% CAGR. As biopharmaceutical companies prioritize product integrity, regulatory compliance, and distribution performance in complex cold chain processes, third-party logistics systems have evolved from a niche transportation service to an essential component enabling temperature optimization, quality assurance, and multi-stage therapeutic distribution across healthcare networks and specialized clinical applications.

The convergence of therapy commercialization, increasing regulatory requirements, personalized medicine development, and global distribution mandates creates momentum in demand. High-quality providers offering superior cold chain performance, cost-effective logistics systems balancing functionality with economics, and specialized variants for critical applications will capture market premiums, while geographic expansion into high-growth Asian healthcare markets and emerging market penetration will drive volume leadership. Biopharmaceutical company emphasis on distribution reliability and product integrity provides structural support.

Segmental Analysis

The market is segmented by type, product, temperature range, therapeutic area, end-use, and region. By type, the market is divided into clinical and commercial. Based on product, the market is categorized into cell therapies and gene therapies. By temperature range, the market is divided into ambient storage, refrigerated storage, ultra-low temperature storage, and cryogenic storage.

Based on therapeutic area, the market is categorized into oncology, neurology, cardiovascular diseases, ophthalmology, and infectious diseases. By end-use, the market is divided into biopharmaceutical companies, CDMOs/CMOs, and others. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Which Cell and Gene Therapy Third-Party Logistics Type Dominates?

Clinical cell and gene therapy third-party logistics account for 83.3% of the market share in 2025. Biopharmaceutical companies increasingly recognize the optimal balance of specialized handling and operational complexity offered by clinical logistics for most therapeutic development applications, particularly in clinical trial support and investigational product distribution. This type addresses both regulatory requirements and quality considerations while providing reliable performance across diverse clinical trial protocols.

This type forms the foundation of most therapy development strategies, as it represents the most critical and operationally intensive logistics requirement in the cell and gene therapy industry. Regulatory compliance standards and extensive quality validation continue to strengthen confidence in clinical logistics systems among biopharmaceutical companies and clinical research organizations.

With increasing recognition of the product integrity and chain of custody requirements in therapeutic development, clinical logistics systems align with both development timelines and regulatory goals, making them the central growth driver of comprehensive commercialization strategies.

By Product, why do Cell Therapies Command the Majority Share?

Cell therapies application is projected to represent 65.5% of third-party logistics demand in 2025, underscoring its role as the primary product segment driving market adoption and growth. Biopharmaceutical companies recognize that cell therapy requirements, including viable cell preservation, strict temperature maintenance, and time-sensitive delivery, often require specialized logistics solutions that conventional distribution systems cannot adequately provide. Third-party logistics providers offer enhanced cold chain management and operational optimization in cell therapy applications.

The segment is supported by the growing nature of CAR-T therapy adoption, requiring sophisticated cold chain systems, and the increasing recognition that specialized logistics solutions can improve product viability and patient outcomes. Companies are increasingly adopting evidence-based distribution guidelines that recommend specific logistics protocols for optimal therapeutic efficacy.

As understanding of cellular product stability advances and distribution requirements become more stringent, third-party logistics will continue to play a crucial role in comprehensive commercialization strategies within the cell therapies market.

By Temperature Range, Which Category Acquires Maximum Prominence?

The ambient storage temperature range segment is projected to account for 35.3% of the cell and gene therapy third-party logistics market in 2025, establishing its position as the leading temperature category.

Logistics providers increasingly recognize the optimal balance of cost-effectiveness and operational simplicity offered by ambient storage for ancillary materials and documentation, particularly in supporting materials and non-temperature-sensitive components. This temperature range addresses both operational requirements and cost considerations while providing proven performance across diverse logistics applications.

The segment is supported by the established nature of ambient storage adoption, requiring minimal specialized infrastructure, and the increasing recognition that ambient storage systems can deliver reliable operational performance for supporting materials.

Logistics providers are increasingly adopting standardized handling protocols that accommodate ambient storage integration for consistent operational outcomes. As understanding of material segregation optimization advances and operational requirements evolve, ambient storage will continue to serve a crucial role in comprehensive logistics strategies within supporting material distribution.

By Therapeutic Area, Which Segment Leads Demand?

Oncology is projected to account for 51.3% of the cell and gene therapy third-party logistics market in 2025, establishing its position as the dominant therapeutic category. The rapid commercialization of CAR-T therapies and other cell-based cancer treatments drives substantial logistics demand, as these products require the most sophisticated cold chain management and time-critical delivery protocols.

Within oncology applications, personalized therapy manufacturing creates complex logistics challenges involving patient-specific material handling, chain of custody documentation, and strict temperature maintenance throughout the distribution cycle. This therapeutic area represents the most mature segment of cell and gene therapy commercialization, with multiple approved products requiring nationwide and global distribution networks.

The complexity of autologous CAR-T logistics, involving patient apheresis material transport to manufacturing facilities and return shipment of final therapeutic products, necessitates specialized third-party logistics capabilities that few providers can deliver at scale.

As oncology pipelines continue expanding with additional cell and gene therapy candidates advancing through clinical development, logistics demand will intensify, requiring further investment in cold chain infrastructure, tracking technologies, and regulatory compliance systems.

By End-use, why do Biopharmaceutical Companies Command the Dominant Market Share?

Biopharmaceutical companies are projected to represent 60.5% of third-party logistics demand in 2025, underscoring their role as the primary customer segment driving market growth. These companies recognize that outsourcing specialized logistics functions enables focus on core competencies in research, development, and manufacturing while leveraging the expertise of dedicated cold chain providers.

The capital-intensive nature of building proprietary cold chain networks makes third-party logistics partnerships strategically attractive, particularly for emerging biotech companies without established distribution infrastructure.

The segment is supported by the increasing complexity of cell and gene therapy distribution requirements, demanding specialized equipment, trained personnel, and regulatory expertise that third-party logistics providers have developed through years of operational experience.

As biopharmaceutical companies expand their therapeutic portfolios and pursue global commercialization strategies, reliance on third-party logistics partners will intensify, creating opportunities for providers that can demonstrate consistent quality performance, regulatory compliance, and scalable capacity across multiple geographic markets and therapeutic modalities.

What are the Drivers, Restraints, and Key Trends of the Cell and Gene Therapy Third-Party Logistics Market?

The cell and gene therapy third-party logistics market is advancing rapidly due to increasing recognition of specialized cold chain's importance and growing demand for reliable distribution systems across the biopharmaceutical sector.

The market faces challenges, including cold chain infrastructure cost considerations, potential for temperature excursions during transportation, and concerns about capacity constraints for ultra-low temperature and cryogenic storage requirements. Innovation in tracking technologies and customized cold chain protocols continues to influence service development and market expansion patterns.

Expansion of Therapy Commercialization and Cold Chain Technologies

The growing adoption of cell and gene therapy commercialization is enabling the development of more sophisticated logistics applications and cold chain management systems that can meet stringent regulatory requirements.

Biopharmaceutical companies offer comprehensive demand for third-party logistics, including ultra-low temperature and cryogenic capabilities that are particularly important for achieving product integrity requirements in therapeutic applications. Advanced cold chain technologies provide access to reliable temperature maintenance that can optimize product viability and reduce quality concerns while maintaining cost-effectiveness for large-scale commercial operations.

Integration of Real-Time Monitoring and Automated Tracking Systems

Modern logistics organizations are incorporating advanced technologies such as IoT-enabled temperature monitoring, blockchain-based chain of custody tracking, and predictive analytics integration to enhance distribution reliability and operational efficiency.

These systems improve visibility, enable continuous performance monitoring, and provide better coordination between manufacturing facilities and clinical sites throughout the distribution cycle. Advanced tracking capabilities also enable customized alert protocols and early identification of temperature deviations or logistical delays, supporting reliable therapeutic delivery.

Analysis of the Cell and Gene Therapy Third-Party Logistics Market by Key Countries

Country	CAGR (2025-2035)
India	13.5%
China	12.8%
Japan	11.9%
USA	10.8%
UK	10.2%
Brazil	10.5%
Germany	9.7%

The cell and gene therapy third-party logistics market is experiencing varied growth globally, with India leading at a 13.5% CAGR through 2035, driven by rapid expansion of clinical trial activities and biopharmaceutical manufacturing infrastructure across major metropolitan centers.

China follows at 12.8%, supported by the world's largest cell therapy clinical pipeline and expanding commercial therapy approvals. Japan records 11.9% growth, with regenerative medicine initiatives and regulatory framework enhancements gaining momentum.

The USA shows 10.8% growth, representing mature commercial therapy distribution and extensive cold chain infrastructure. UK demonstrates 10.2% growth, emphasizing advanced therapy medicinal product (ATMP) logistics development.

Brazil records 10.5% growth with emerging biopharmaceutical sector and clinical trial expansion, while Germany shows 9.7% growth, representing steady commercial therapy adoption and logistics infrastructure upgrades in established healthcare networks.

How does India Demonstrate Growing Potential with Biopharmaceutical Sector Leadership?

The cell and gene therapy third-party logistics market in India is projected to exhibit robust growth with a CAGR of 13.5% through 2035, driven by ongoing biopharmaceutical sector expansion and increasing recognition of specialized logistics as an essential service component for clinical trial support. The country's expanding clinical research activities and growing availability of specialized cold chain infrastructure are creating significant opportunities for third-party logistics adoption across both domestic trial sites and contract manufacturing facilities.

Major international and domestic logistics providers are establishing comprehensive distribution and cold chain networks to serve the growing population of biopharmaceutical companies and research organizations requiring specialized logistics services across cell and gene therapy applications throughout India's major pharmaceutical hubs.

The Indian government's strategic emphasis on biotechnology development and clinical trial acceleration is driving substantial investments in specialized cold chain capabilities. This policy support, combined with the country's large domestic pharmaceutical manufacturing sector and expanding clinical research requirements, creates a favorable environment for third-party logistics market development. Indian biopharmaceutical companies are increasingly focusing on advanced therapy development to improve therapeutic capabilities, with specialized logistics representing a key enabler in this commercialization transformation.

• Government initiatives supporting biotechnology development and clinical research expansion are driving demand for high-quality third-party logistics services.
• Cold chain infrastructure expansion and tracking system development are supporting appropriate utilization of specialized logistics among companies and research facilities nationwide.
• Biopharmaceutical developers and contract research organizations are increasingly integrating advanced logistics systems into distribution infrastructure, creating new operational capabilities.
• Rising healthcare investment and growing awareness of therapeutic innovation are accelerating specialized logistics adoption.

How does China Demonstrate Exceptional Market Potential with Cell Therapy Growth?

The cell and gene therapy third-party logistics market in China is expanding at a CAGR of 12.8%, supported by increasing cell therapy clinical development, growing commercialization activities, and advancing cold chain infrastructure presence across the country's major biopharmaceutical corridors.

The country's massive clinical trial sector and increasing recognition of specialized logistics systems are driving demand for reliable cold chain solutions in both investigational and commercial therapeutic applications. International logistics companies and domestic providers are establishing comprehensive distribution channels to serve the growing demand for quality cold chain services while supporting the country's position as a global cell therapy development leader.

China's biopharmaceutical sector continues to benefit from favorable government policies, expanding manufacturing capabilities, and cost-competitive cold chain infrastructure development. The country's focus on becoming a global regenerative medicine hub is driving investments in specialized logistics technology and distribution infrastructure. This development is particularly important for cell and gene therapy logistics, as companies seek reliable domestic sources for critical distribution services to reduce dependency on international providers and improve supply chain security.

• Rising awareness about therapeutic innovation and improving cold chain capabilities are creating opportunities for specialized third-party logistics.
• Growing biopharmaceutical infrastructure development and technology adoption are supporting increased access to high-quality logistics services among organizations.
• Expanding clinical pipeline and commercial therapy approvals are driving innovative applications of specialized logistics in patient treatment and clinical research.
• Infrastructure capacity expansion is enabling domestic provision of advanced cold chain technologies, supporting market growth and capability transfer.

How will the Cell and Gene Therapy Third-Party Logistics Sector Expand in Brazil?

The cell and gene therapy third-party logistics market in Brazil is projected to exhibit strong growth with a CAGR of 10.5% through 2035, driven by clinical trial expansion momentum and cold chain infrastructure capabilities. The country's emerging biopharmaceutical development programs and growing technical expertise are creating significant opportunities for third-party logistics adoption across both domestic and regional markets.

Logistics providers are leveraging their infrastructure development initiatives to serve the growing demand for specialized cold chain systems while supporting the country's position as a regional biotechnology adopter. The market benefits from favorable healthcare investment programs, expanding clinical research capabilities, and cost-competitive cold chain systems. This development is particularly important for cell and gene therapy logistics, as companies seek reliable regional sources for distribution services to maintain operational advantages in clinical and commercial therapy markets.

Strategic Market Considerations:

• Clinical trial and early commercial therapy segments leading growth with focus on cold chain reliability and regulatory compliance applications
• Regional infrastructure requirements are driving a diverse service portfolio from basic cold chain systems to advanced cryogenic platforms
• Infrastructure investment advantages supporting competitive positioning in South American markets
• Government biotechnology initiatives beginning to influence logistics standards and operational requirements

How does USA Maintain Growth amid Biopharmaceutical Technology Leadership

The USA's advanced healthcare market demonstrates sophisticated logistics deployment with documented third-party logistics effectiveness in commercial CAR-T distribution and clinical trial applications through integration with existing biopharmaceutical infrastructure and regulatory systems. The country leverages technical expertise in cold chain management and quality compliance to maintain a 10.8% CAGR through 2035. Biopharmaceutical operations centers, including major therapy manufacturers and specialty pharmacies, showcase advanced logistics integrations where third-party logistics systems integrate with comprehensive quality management platforms and regulatory tracking systems to optimize distribution reliability and compliance effectiveness.

Biopharmaceutical companies prioritize product integrity and regulatory compliance in commercialization strategies, creating demand for premium third-party logistics services with advanced features, including real-time monitoring and integration with US FDA requirements. The market benefits from established cold chain infrastructure and willingness to invest in specialized logistics systems that provide long-term quality benefits and compliance with regulatory standards.

Strategic Market Considerations:

• Commercial therapy distribution and clinical trial support leading growth with focus on product integrity and regulatory compliance applications
• Regional operational requirements are driving a diverse service portfolio from basic cold chain systems to advanced cryogenic platforms
• Capacity development challenges offset by domestic logistics provider expansion and infrastructure initiatives
• Regulatory compliance requirements influencing procurement standards and operational protocols

What is the Outlook for the Market in Germany?

Germany's market expansion benefits from diverse biopharmaceutical demand, including ATMP development programs and clinical research expansion that increasingly incorporate specialized third-party logistics solutions for therapeutic distribution applications. The country maintains a 9.7% CAGR through 2035, driven by rising regulatory harmonization and increasing adoption of advanced therapy benefits, including superior cold chain capabilities and reduced distribution complexity.

Market dynamics focus on cost-effective third-party logistics that balance advanced performance features with affordability considerations important to German biopharmaceutical companies. Growing therapy commercialization creates demand for advanced logistics systems in new product launches and infrastructure development projects.

Strategic Market Considerations:

• ATMP and clinical research segments leading growth with focus on regulatory compliance and cold chain reliability applications
• Regional operational requirements are driving a diverse service portfolio from basic cold chain systems to advanced cryogenic platforms
• Capacity development challenges offset by potential partnerships with European logistics providers
• Regulatory harmonization initiatives beginning to influence procurement standards and operational requirements

How will the Scope for Cell and Gene Therapy Third-Party Logistics Expand in the UK?

The UK's market expansion benefits from diverse biopharmaceutical demand, including ATMP regulatory framework implementation and therapy commercialization programs. The country maintains a 10.2% CAGR through 2035, driven by rising regulatory clarity requirements and increasing preference for specialized logistics through established cold chain infrastructure channels.

The market prioritizes advanced performance features, including quality monitoring and integration with comprehensive regulatory platforms that reflect UK healthcare expectations for therapeutic excellence and distribution reliability.

British biopharmaceutical companies focus on regulatory compliance in commercialization strategies, creating demand for premium third-party logistics with advanced features including performance tracking and comprehensive quality support. The market benefits from established cold chain infrastructure and investment in quality assurance technology that provides long-term therapeutic benefits.

Strategic Market Considerations:

• ATMP commercialization and clinical research segments leading growth with focus on regulatory compliance and cold chain reliability applications
• Regional operational requirements are driving a diverse service portfolio from basic cold chain systems to advanced cryogenic platforms
• Capacity development challenges offset by potential partnerships with European cold chain suppliers
• Regulatory framework initiatives beginning to influence procurement standards and operational requirements

What is the Outlook for the Cell and Gene Therapy Third-Party Logistics Market in Japan?

Japan demonstrates steady market development with an 11.9% CAGR through 2035, distinguished by companies' preference for high-quality third-party logistics that integrate seamlessly with existing healthcare systems and provide reliable operational performance in specialized applications.

The market prioritizes advanced features, including precision temperature management, quality validation, and integration with comprehensive regulatory platforms that reflect Japanese expectations for technology sophistication and operational excellence.

Japanese biopharmaceutical companies focus on product integrity and quality precision in commercialization strategies, creating demand for premium third-party logistics with advanced features including automated temperature monitoring and comprehensive regulatory support. The market benefits from established healthcare research infrastructure and investment in quality optimization technology that provides long-term therapeutic benefits.

Strategic Market Indicators:

• Regenerative medicine programs and commercial therapy launches focus on precision cold chain systems with advanced temperature profiles and high-reliability capabilities
• Integration requirements with existing quality management systems and regulatory platforms
• Emphasis on third-party logistics reliability and long-term operational performance in established healthcare applications

Europe Market Split by Country

The cell and gene therapy third-party logistics market in Europe is projected to grow from USD 3.7 billion in 2025 to USD 10.8 billion by 2035, registering a CAGR of 11.4% over the forecast period. Germany is expected to maintain its leadership position with a 28.5% market share in 2025, rising to 29.2% by 2035, supported by its advanced biopharmaceutical infrastructure, comprehensive ATMP development programs, and strong regulatory framework throughout major pharmaceutical corridors.

France follows with a 22.4% share in 2025, projected to reach 23.1% by 2035, driven by cell therapy commercialization protocols, cold chain integration, and expanding clinical research networks serving both domestic and international markets. The UK holds a 19.6% share in 2025, expected to increase to 20.3% by 2035, supported by ATMP regulatory implementation and growing adoption of specialized logistics technologies.

Italy commands a 13.8% share in 2025, projected to reach 14.2% by 2035, while Spain accounts for 10.2% in 2025, expected to reach 10.6% by 2035. The rest of Europe, including Nordic countries, Eastern Europe, and smaller Western European markets, is anticipated to hold 5.5% in 2025, declining slightly to 2.6% by 2035, attributed to market consolidation toward larger core markets with established biopharmaceutical infrastructure and cold chain capabilities.

Competitive Landscape of the Cell and Gene Therapy Third-Party Logistics Market

The cell and gene therapy third-party logistics market is characterized by competition among established healthcare logistics providers, pharmaceutical distributors, and specialized cold chain specialists focused on delivering high-quality, reliable, and operationally optimized logistics services.

Companies are investing in cold chain technology advancement, quality system enhancement, strategic biopharmaceutical partnerships, and regulatory compliance services to deliver effective, efficient, and reliable logistics solutions that meet stringent healthcare operational and regulatory requirements. Temperature validation, quality assurance protocols, and distribution network optimization strategies are central to strengthening service portfolios and market presence.

Cencora Corporation leads the market with a 12.8% market share, offering comprehensive high-quality third-party logistics with a focus on operational reliability and cold chain excellence for biopharmaceutical applications.

Cardinal Health provides specialized logistics solutions with emphasis on commercial therapy distribution and comprehensive regulatory support services. McKesson Corporation focuses on advanced cold chain technologies and customized distribution solutions for cell and gene therapy systems serving North American markets. EVERSANA delivers integrated commercialization solutions with strong patient services capabilities and logistics expertise.

Knipper Health operates with a focus on bringing innovative logistics technologies to specialized therapeutic applications and emerging therapy markets. DHL provides comprehensive logistics portfolios, including premium cold chain services, across multiple therapeutic applications and operational requirements.

Kuehne + Nagel specializes in advanced temperature-controlled systems and supply chain solutions for biopharmaceutical applications with emphasis on global reach. FedEx provides reliable healthcare logistics and technical expertise to enhance market accessibility and company access to essential cold chain services.

United Parcel Service (UPS), Arvato SE focus on specialized healthcare logistics solutions and premium service offerings for high-value therapeutic applications, emphasizing quality differentiation and technical innovation through advanced tracking strategies.

Key Players in the Cell and Gene Therapy Third-Party Logistics Market

• Cencora Corporation
• Cardinal Health
• McKesson Corporation
• EVERSANA
• Knipper Health
• DHL (DE)
• Kuehne + Nagel
• Arvato SE
• FedEx
• United Parcel Service (UPS)

Scope of the Report

Items	Values
Quantitative Units (2025)	USD 11.9 Billion
Type	Clinical, Commercial
Product	Cell Therapies, Gene Therapies
Temperature Range	Ambient Storage, Refrigerated Storage, Ultra-Low Temperature Storage, Cryogenic Storage
Therapeutic Area	Oncology, Neurology, Cardiovascular Diseases, Ophthalmology, Infectious Diseases
End-use	Biopharmaceutical Companies, CDMOs/CMOs, Others
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Countries Covered	USA, Germany, UK, Japan, India, China, Brazil and 40+ countries
Key Companies Profiled	Cencora Corporation, Cardinal Health, McKesson Corporation, EVERSANA, Knipper Health, DHL, Kuehne + Nagel, Arvato SE, FedEx, and United Parcel Service (UPS)
Additional Attributes	Dollar sales by type, product, temperature range, therapeutic area, and end-use, regional demand trends, competitive landscape, company preferences for specific logistics technologies, integration with cold chain systems, innovations in tracking technologies, temperature monitoring, and distribution optimization

Cell and Gene Therapy Third-Party Logistics Market by Segments

• Type :

  • Clinical
  • Commercial

• Product :

  • Cell Therapies
  • Gene Therapies

• Temperature Range :

  • Ambient Storage
  • Refrigerated Storage
  • Ultra-Low Temperature Storage
  • Cryogenic Storage

• Therapeutic Area :

  • Oncology
  • Neurology
  • Cardiovascular Diseases
  • Ophthalmology
  • Infectious Diseases

• End-use :

  • Biopharmaceutical Companies
  • CDMOs/CMOs
  • Others

• Region :

  • North America
    • USA
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Nordic
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Chile
    • Rest of Latin America
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Other African Countries
    • Rest of Middle East & Africa